Abstract: Provided are methods of generating a metabolically mature human cell selected from the group consisting of a cardiomyocyte, a pancreatic beta cell, and a neuronal cell, using an effective concentration of a conjugated fatty acid and optionally a nonconjugated fatty acid selected from the group consisting of: a monounsaturated omega-9 fatty acid, palmitic acid, linoleic acid (LA) and a short chain fatty acid. Also provided are isolated populations of metabolically mature human cells, and methods and kits using same for selecting a compound for toxicity to the cells.

Abstract: Methods, compositions and kits for reducing renal tissue toxicity in a subject caused by a kidney damaging agent are provided. The methods comprise administering to the subject: (i) a kidney damaging agent; (ii) a PPARA activator; and (iii) an inhibitor of a cellular pathway selected from the group consisting of C/EBP, PPARG, ER stress, GLUT2 and SGLT1/2; or (i) a kidney damaging agent; (ii) a SGLT2 inhibitor; and (iii) a PPARA activator, a C/EBP inhibitor, a PPARG inhibitor, or an ER stress inhibitor.

Abstract: Methods of treating coronavirus infection, or decreasing the risk of symptomatic infection, by administering a peroxisome proliferator-activated receptor alpha (PPARA) agonist or an inositol-requiring enzyme 1 (IRE1) pathway inhibitor are provided.

Abstract: Methods of generating organoids on multi-well plates are provided by depositing a polymeric solution comprising cells under conditions which result in a homogenous population of organoids, which can be used for high throughput analysis for drug screening and for determining treatment regimens of a drug.

Abstract: A method for reducing renal tissue toxicity in a subject caused by a kidney damaging agent is disclosed. The method comprises administering to the subject: (i) a kidney damaging agent; and (ii) an inhibitor of glucose reabsorption.

Abstract: There are provided herein methods, devices, kits and systems utilizing respiratory mask for delivering pressurized fluid to a subject via inhalation in an efficient manner. The fluid may include gas and/or drug and by utilizing the methods, devices, kits and systems provided, efficient drug delivery to the subject's airways is achieved. The systems, devices, kits and methods further allow inducing insufflation/exsufflation in particular in subjects having impaired suffering from low neuromotor capacity, such as spinal cord injuries (SCI) patients.